LEE SHEAU LONG has a total of 26 patent applications. Its first patent ever was published in 2007. It filed its patents most often in EPO (European Patent Office), Taiwan and Republic of Korea. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are ICEUTICA INC, PROBIONOV and INNOLIFE CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 6 | |
#2 | Taiwan | 6 | |
#3 | Republic of Korea | 4 | |
#4 | United States | 4 | |
#5 | China | 3 | |
#6 | WIPO (World Intellectual Property Organization) | 3 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Steroids |
# | Name | Total Patents |
---|---|---|
#1 | Lee Yu-Chieh | 19 |
#2 | Lee Sheau-Long | 17 |
#3 | Hua Kuo-Feng | 16 |
#4 | Chen Ann | 8 |
#5 | Lee Yu Chieh | 7 |
#6 | Lee Sheau Long | 7 |
#7 | Hua Kuo Feng | 7 |
#8 | Hsu Wan-Han | 5 |
#9 | Ka Shuk-Man | 4 |
#10 | Ka Shuk Man | 4 |
Publication | Filing date | Title |
---|---|---|
EP3790556A1 | Use of ginsenoside m1 for treating cancer | |
KR20210003715A | Use of ginsenoside M1 to treat Huntington's disease | |
US2021023104A1 | Use of ginsenoside m1 for manufacturing medicament for treating oral cancer | |
CN107635564A | Ginsenoside M1 is used for the purposes for preventing or treating silicosis | |
TW201630611A | Use of ginsenoside m1 for treating iga nephropathy | |
US2017087170A1 | Use of ginsenoside M1 for inhibiting renal fibrosis | |
EP3137089A1 | Use of ginsenoside m1 for treating lupus nephritis |